title: Evidences for pharmacokinetic interaction of riluzole and topiramate with pilocarpine in pilocarpine-induced seizures in rats.
abstract: In this study we investigated the effectiveness of two antiepileptic drugs: riluzole and topiramate against pilocarpine-induced seizures, which are considered to be a model of intractable epilepsy commonly used to investigate the antiepileptic effect of drugs and mechanisms of epileptogenesis. Seizures and status epilepticus were induced by pilocarpine in adult male Wistar rats. Riluzole (1-4mg/kg) administered intraperitoneally before pilocarpine dose-dependently protected rats against seizures with the anticonvulsant ED(50) value (50% effective anticonvulsant dose) of 1.8 (1.3-2.6)mg/kg. In contrast, riluzole at 8 and 12mg/kg administered after the onset of pilocarpine-induced seizures affected neither status epilepticus nor mortality of rats. Topiramate significantly enhanced convulsive action of pilocarpine, lowering the convulsant CD(50) value (50% effective convulsant dose) of pilocarpine from 350.8 (329.2-373.8) to 246.4 (218.6-278.2)mg/kg. Riluzole (4mg/kg) lowered plasma and brain concentration of pilocarpine administered at a dose of 400mg/kg from 168.0+/-8.6 to 75.3+/-19.9microg/ml and from 193.7+/-6.6 to 97.0+/-26.1microg/g, respectively. Topiramate (200mg/kg) increased plasma and brain concentration of pilocarpine administered at a dose of 300mg/kg from 78.1+/-2.9 to 106.0+/-6.8microg/ml and from 138.4+/-5.0 to 155.2+/-5.1microg/g, respectively. It seems that both anticonvulsant effect exerted by riluzole and proconvulsant effect exerted by topiramate in pilocarpine model of seizures are due to a pharmacokinetic interaction. Therefore, we postulate that the concentration of pilocarpine should be measured routinely whenever the anticonvulsant effect of drugs is determined in the pilocarpine model of seizures.
authors.affiliation: Department of Toxicology, Institute of Agricultural Medicine, Lublin, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Zgrajka
authors.forename: Dorota
authors.initials: D
authors.lastname: Nieoczym
authors.forename: Mirosław
authors.initials: M
authors.lastname: Czuczwar
authors.forename: Jacek
authors.initials: J
authors.lastname: Kiś
authors.forename: Wojciech
authors.initials: W
authors.lastname: Brzana
authors.forename: Piotr
authors.initials: P
authors.lastname: Wlaź
authors.forename: Waldemar A
authors.initials: WA
authors.lastname: Turski
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000493:pharmacokinetics; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D003292:Convulsants / Q000493:pharmacokinetics; D004347:Drug Interactions; D005632:Fructose / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008297:Male; D010862:Pilocarpine / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D019782:Riluzole / Q000493:pharmacokinetics*; D012640:Seizures / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D013226:Status Epilepticus / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D000077236:Topiramate
chemical_list: D000927:Anticonvulsants; D003292:Convulsants; D010862:Pilocarpine; D000077236:Topiramate; D005632:Fructose; D019782:Riluzole